|
| Product Name: | B581 | | Synonyms: | CYS-((R))-VAL-((R))-PHE-MET;FTASE INHIBITOR I;H-CYS-(R)-VAL-(R)-PHE-MET-OH;B581;N-[(S)-2-((R)-2-AMINO-3-MERCAPTO-PROPYLAMINO)-3-METHYL-BUTYL]-PHE-MET-OH;N-[2(S)-(2(R)-2-AMINO-3-MERCAPTOPROPYLAMINO)-3-METHYLBUTYL]-L-PHENYLALANYL-L-METHIONINE;N-[2(S)-[2(R)-AMINO-3-MERCAPTOPROPYLAMINO]-3-METHYL-BUTYL]-PHE-MET;N-[2(S)-[2(R)-AMINO-3-MERCAPTOPROPYLAMINO]-3-METHYLBUTYL]-PHE-MET-OH | | CAS: | 149759-96-6 | | MF: | C22H38N4O3S2 | | MW: | 470.69 | | EINECS: | | | Product Categories: | | | Mol File: | 149759-96-6.mol |  |
| Boiling point | 716.1±60.0 °C(Predicted) | | density | 1.161±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | H2O: soluble | | form | solid | | pka | 3.04±0.10(Predicted) | | color | white |
| Description | FTase inhibitor I is a potent inhibitor of farnesyltransferase (FTase; IC50 = 21 nM) that is greater than 30-fold selective for FTase over geranylgeranyl transferase (GGTase; IC50 = 790 nM). It prevents farnesylation of Ras and inhibits proliferation of cells transformed by Ras farnesylation. In a dog model of subarachnoid hemorrhage, it reduces GTP-Ras in spastic basilar arteries, decreases angiographic vasospasm, and improves clinical scores. | | Uses | FTase Inhibitor I is a potent, selective, peptidomimetic FTase inhibitor. | | Definition | ChEBI: A dipeptide obtained from the tetrapeptide Cys-Val-Phe-Met by reduction of the amide carbonyl groups of the Cys and Val residues. | | Enzyme inhibitor | This cell-permeable CAAX peptidomimetic (FW = 470.70 g/mol; FWtrifluoracetate-salt = 583.71 g/mol; CAS 149759-96-6), named as N-[2(S)- (2(R)-2-amino-3-mercaptopropylamino)-3-methylbutyl]-L-phenylalanyl-L methionine), binds to and prevents protein farnesyltransferase (IC50 = 21 nM) from interacting with C-terminal L-Cys-L-Val-L-Phe-L-Met substrate recognition sequences that are present in its natural substrates. Otherwise hydrophilic proteins associate with membranes by means of enzymatic attachment of hydrophobic moieties to their C-termini. Whereas prenylation occurs in the cytosol, post-prenylation processing is accomplished on the cytoplasmic surface of the endoplasmic reticulum and Golgi apparatus. B581 inhibits prenylation and processing of H-ras and lamin A. B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. |
| | B581 Preparation Products And Raw materials |
|
